The TAME trial's statistical design must avoid significant findings in any single disease to prevent premature study stoppage, except for mortality.

“and the important thing of the cluster is that we cannot do time study imagine we do a time study and in two years cardiovascular disease comes up as as significant and there's an insignificant reduction of cardiovascular mortality and the fda will say hey we have to stop the study because we cannot go with the study when with placebo right and it will ruin it for us so the whole the whole problem of the statistics obtain is to make sure that we're not getting to any significant in any disease just to trends and that the only way to stop by the way the one one way to stop the study is if mortality is significant that will trigger a stoppage of this study otherwise what will stop the study is the integral approach of right so statistically you just can't your biggest mistake here is overpowering the study for mortality and therefore appropriately powering the study for subs subsets of mortality yes is that is that a safe assessment substance of mortality you mean diseases disease specific mortality is what i mean yes”